Search in:

Expert Review of Clinical Pharmacology Volume 12, 2019 - Issue 2

Submit an article Journal homepage

1,075

Views

CrossRef citations to date

Altmetric

Review

Novel developments of hepatitis B: treatment goals, agents and monitoring tools

Lung-Yi MakDepartment of Medicine, The University of Hong Kong, Hong Kong, Hong KongView further author information

Wai-Kay SetoDepartment of Medicine, The University of Hong Kong, Hong Kong, Hong Kong;Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China;State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong KongView further author information

James FungDepartment of Medicine, The University of Hong Kong, Hong Kong, Hong Kong;State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong KongView further author information

Man-Fung YuenDepartment of Medicine, The University of Hong Kong, Hong Kong, Hong Kong;State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong KongCorrespondence[email protected]
View further author information

Pages 109-120 | Received 14 Oct 2018, Accepted 07 Jan 2019, Published online: 21 Jan 2019

Cite this article
https://doi.org/10.1080/17512433.2019.1567327
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (27)

Rose Mcgready, Glen Mola, Marcus J. Rijken, François H. Nosten & Theonest Mutabingwa. 2024. Manson's Tropical Diseases. Manson's Tropical Diseases 1188 1204 .

Qianqian Tang, Jun Ye, Yafei Zhang, Peixin Zhang, Guomei Xia, Jie Zhu, Shaofeng Wei, Xu Li & Zhenhua Zhang. (2023) Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy. BMC Infectious Diseases 23:1.
Crossref

Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang & Fuqiang Cui. (2023) Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. The Lancet Regional Health - Western Pacific 35, pages 100738.
Crossref

Lung-Yi Mak & Man-Fung Yuen. 2023. Comprehensive Guide to Hepatitis Advances. Comprehensive Guide to Hepatitis Advances 205 227 .

Bei Jiang, Qinghai Dai, Yamin Liu, Guangxin Yu & Yuqiang Mi. (2022) Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy. Infectious Agents and Cancer 17:1.
Crossref

Paul Martin, Mindie H. Nguyen, Douglas T. Dieterich, Daryl T.-Y. Lau, Harry L.A. Janssen, Marion G. Peters & Ira M. Jacobson. (2022) Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clinical Gastroenterology and Hepatology 20:8, pages 1766-1775.
Crossref

Alix Boisson, Varun Goel, Marcel Yotebieng, Jonathan B. Parr, Bruce Fried & Peyton Thompson. (2022) Implementation Approaches for Introducing and Overcoming Barriers to Hepatitis B Birth-Dose Vaccine in sub-Saharan Africa. Global Health: Science and Practice 10:1, pages e2100277.
Crossref

Nerma Čustović & Senija Rašić. (2022) Relationship of serum adiponectin and resistin levels with the severity of liver fibrosis in patients with chronic hepatitis B. Journal of Medical Biochemistry 41:2, pages 176-183.
Crossref

Qing-Juan Wu, Wen-Liang Lv, Juan-Mei Li, Ting-Ting Zhang, Wen-Hui Zhou, Qiang Zhang, Jiu-Chong Wang, Qing-Nan Wang, Zi-Ang Yao, Rui Qiang, Si-Tong Chen, Xin Zhao, Shuang Liu, Zheng-Min Cao, Lei Xu, Gao-Hui Li, Jing Chen & Li Wang. (2021) YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial. Trials 22:1.
Crossref

Huimin Kong, Enguo Ju, Ke Yi, Weiguo Xu, Yeh‐Hsing Lao, Du Cheng, Qi Zhang, Yu Tao, Mingqiang Li & Jianxun Ding. (2021) Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Advanced Science 8:24, pages 2102051.
Crossref

Lisa Sandmann & Markus Cornberg. (2021) Towards eradication of HBV: Treatment approaches and status of clinical trials. Current Opinion in Pharmacology 60, pages 232-240.
Crossref

Guiqiang Wang & Zhongping Duan. (2021) Guidelines for Prevention and Treatment of Chronic Hepatitis B. Journal of Clinical and Translational Hepatology 000:000, pages 000-000.
Crossref

Hong Zhang, Fengjiao Wang, Xiaoxue Zhu, Yunfu Chen, Hong Chen, Xiaojiao Li, Min Wu, Cuiyun Li, Jingrui Liu, Yingjun Zhang, Yanhua Ding & Junqi Niu. (2021) Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection. Clinical Infectious Diseases 73:2, pages 175-182.
Crossref

Mona Nasser, Naglaa Zayed, Hadeel Gamal Eldeen, Mahmoud Abdo, Younan Kabara & Magdy Elserafy. (2021) Inter-method variability of hepatitis B surface antigen quantification in a cohort of Egyptian patients with chronic hepatitis B virus. Arab Journal of Gastroenterology 22:2, pages 151-157.
Crossref

Lung‐Yi Mak, Gavin Cloherty, Danny Ka‐Ho Wong, Jeffrey Gersch, Wai‐Kay Seto, James Fung & Man‐Fung Yuen. (2021) HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. Hepatology 73:6, pages 2167-2179.
Crossref

Minghui Li, Lu Zhang, Yao Lu, Qiqi Chen, Huihui Lu, Fangfang Sun, Zhan Zeng, Gang Wan, Linqing Zhao & Yao Xie. (2020) Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virologica Sinica 36:2, pages 311-320.
Crossref

Christine I. Wooddell, Adam J. Gehring, Man-Fung Yuen & Bruce D. Given. (2021) RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. Viruses 13:4, pages 581.
Crossref

Jung Hyun Lim, Jung Hwan Yu, Young Ju Suh, Jin-Woo Lee & Young-Joo Jin. (2021) Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine 100:39, pages e27417.
Crossref

Zhan-qing Zhang, Bi-sheng Shi, Wei Lu, Dan-ping Liu, Dan Huang & Yan-ling Feng. (2020) Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients. Gastroenterología y Hepatología 43:9, pages 526-536.
Crossref

Fabien Zoulim, Oliver Lenz, Joris J. Vandenbossche, Willem Talloen, Thierry Verbinnen, Iurie Moscalu, Adrian Streinu-Cercel, Stefan Bourgeois, Maria Buti, Javier Crespo, Juan Manuel Pascasio, Christoph Sarrazin, Thomas Vanwolleghem, Umesh Shukla, John Fry & Jeysen Z. Yogaratnam. (2020) JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology 159:2, pages 521-533.e9.
Crossref

Maria Gerasi, Efseveia Frakolaki, Georgios Papadakis, Anna Chalari, Nikolaos Lougiakis, Panagiotis Marakos, Nicole Pouli & Niki Vassilaki. (2020) Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines. Bioorganic Chemistry 98, pages 103580.
Crossref

Lung-Yi Mak. (2020) Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought. The Lancet Gastroenterology & Hepatology 5:5, pages 420-421.
Crossref

Zhaozhong Zhu, Yunshi Fan, Yang Liu, Taijiao Jiang, Yang Cao & Yousong Peng. (2020) Prediction of antiviral drugs against African swine fever viruses based on protein–protein interaction analysis. PeerJ 8, pages e8855.
Crossref

Jennifer C. Price & Debika Bhattacharya. (2020) Editorial: HBV-the promise of a new era in therapeutics. Alimentary Pharmacology & Therapeutics 51:4, pages 479-480.
Crossref

Lung-Yi Mak, Wai-Kay Seto, James Fung & Man-Fung Yuen. (2019) Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatology International 14:1, pages 35-46.
Crossref

Lung-Yi Mak, Wai-Kay Seto & Man-Fung Yuen. (2019) Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. Current Hepatology Reports 18:4, pages 503-511.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Novel developments of hepatitis B: treatment goals, agents and monitoring tools

Articles from other publishers (27)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Novel developments of hepatitis B: treatment goals, agents and monitoring tools

Citations (27)

Articles from other publishers (27)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date